Abstract 2163P
Background
In France, cancer is the leading cause of death among men and the second leading cause among women. Currently, supportive care provided to cancer patients in community pharmacies are heterogeneous across the country. In order to structure and standardize pharmaceuticalsupportfor all cancer patients in primary care, TotumLab foundation has created the OncoPharma certification.
Methods
The OncoPharma certification is based on a framework that covers the activities of dispensing treatments andsupportingcancer patients, caregivers and relatives, from the time of diagnosis, during and after cancer, by the entire pharmacy team. The framework presents certified characteristics, the way to implement them, as well as documentary ressources and requested internal controls to ensure compliance. The development of the certification framework is the result of a multidisciplinary collaborative effort, bringing together all healthcare professionals involved in cancer patients care. The OncoPharma certification is accessible to all community pharmacies in France.
Results
In the certification framework, patient care is structured around 14 operational characteristics that are proposed and adapted to each individual situation. Since June 2022, the OncoPharma certification framework has been accredited by the French accreditation committee (COFRAC). This document allowed for the publication of the first clinical guideline for the management of cancer patients in community pharmacies by the Francophone Association of Supportive Oncology Care (AFSOS). As of April 2023, two pharmacies have been certified under OncoPharma, and over 40 others are in the process of certification.
Conclusions
This innovative project is the result of collective and multidisciplinary work to improve the quality of life of patients living with cancer. It promotes communication and coordination among healthcare professionals, as well as training and upskilling of pharmacy teams. This project is part of the continuous improvement and value creation in healthcare. Thanks to the Oncopharma certification, the community pharmacist plays a central role in the care of people with cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
TotumLab.
Funding
TotumLab.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2184TiP - Extensive cardiovascular characterization and follow-up of patients receiving immune checkpoint inhibitors: A prospective multicenter study
Presenter: Danielle Delombaerde
Session: Poster session 07
2185TiP - Belgian FORX trial: FOod interventions to Reduce immunotherapy toXicity
Presenter: Marthe Verhaert
Session: Poster session 07
2186P - KN046 in patients with thymic carcinoma: A prospective, single-arm, multi-centre, phase II study
Presenter: Wentao Fang
Session: Poster session 07
2187P - Efficacy and safety of gemcitabine as maintenance treatment in unresectable malignant pleural mesothelioma: A phase II randomized study
Presenter: Mohamed Emam Sobeih
Session: Poster session 07
2188P - First-line combination of toripalimab and chemotherapy in advanced thymic carcinoma: A prospective, single-arm, phase II trial
Presenter: hui'yang shi
Session: Poster session 07
2189P - Combining SBRT with GM-CSF and Peg-IFNα to induce abscopal effects in previously treated patients with stage IV thymic tumors
Presenter: Boyan Wang
Session: Poster session 07
2190P - First-line atezolizumab in combination with platinum etoposide in patients with metastatic lung large cell neuroendocrine carcinoma (LCNEC)
Presenter: Georgios Evangelou
Session: Poster session 07
2191P - Real-world outcomes of patients with malignant pleural mesothelioma (MPM) treated with combination nivolumab and ipilimumab in the first- or later line setting
Presenter: Sabine Schmid
Session: Poster session 07
2192P - Quality of life (QoL) of patients (pts) with advanced malignant pleural mesothelioma (aMPM) treated in a real-world setting
Presenter: Abhenil Mittal
Session: Poster session 07
2193P - Real-world evidence of the impact of immunotherapy (IT) on overall survival (OS) of patients (p) with malignant pleural mesothelioma (MPM) adjusted for tumor histology
Presenter: Susana Cedres Perez
Session: Poster session 07